Table II Regression analysis for treatment effects on tumor growth and Kaplan-Meier analysis for treatment effects on survival. Data are listed as mean with their 95% confidence intervals in parentheses
TreatmentnGrowth curveav(d)rTumor doubling time(d)bTumor growth delay(d)cMedian survival30-days survival
LLCControl7In(v) = 0.2009d–1.690.95093.46 (3.23–3.68)8.45 (8.27–8.64)18.0 (13.59–26.41)0.00
VNP7In(v) = 0.1583d–1.810.97334.44 (4.27–4.61)11.43 (11.22–11.64)35.0 (25.92–42.08)**0.71
VNPpadhEEnd7In(v) = 0.1341d–1.950.96525.21 (4.99–5.42)14.54 (14.22–14.86)49.0 (33.46–52.54)0.86
B16F10Control8In(v) = 0.2342d–1.770.98142.96 (2.85–3.08)7.56 (7.48–7.64)11.5 (9.42–13.08)0.00
VNP8In(v) = 0.1186d–1.530.95865.84 (5.70–5.98)12.90 (12.67–13.05)19.5 (13.60–26.65)**0.00
VNPpadhEEnd8In(v) = 0.0996d–1.700.98336.96 (6.86–7.07)17.07 (16.97–17.17)28.5 (16.18–32.82)**0.25
  • a Regression growth curves summarize volume (V, cm3) dependence on time (d, days) from initial treatment, with correlation coefficients indicated by r.

  • b Tumor doubling time was derived from exponential growth curves.

  • c Growth delay was determined by assessing the time interval to 1000 mm3, (mean ± S.D., ;†p < 0.0001, VNPpadhEEndostatin vs. VNP, **p < 0.01). Median survival time was analyzed by software MedCalc and is listed with their 95% confidence intervals in parentheses. Significance is indicated as **p < 0.01 (in Lewis lung carcinoma (LLC) treatment: VNP vs. control, in B16F10 treatment: VNP vs. control, VNPpadhEEndostatin vs. VNP), ;†p < 0.0001 (in LLC treatment: VNPpadhEEndostatin vs. VNP).